Mr. Francois Roberge reports

JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA

LSL Pharma Group Inc. has signed a binding term sheet with Instapill Pvt. Ltd. for the supply of private label loratadine 10-milligram rapid-dissolve tablets (RDT) to Canadian retailers. The product is bioequivalent to Claritin RDT and positions LSL Pharma in the large, recurring over-the-counter (OTC) allergy category, addressing strong and growing consumer demand. The Canadian OTC allergy category is estimated at $60-million and growing at 8 per cent per year.

This agreement builds on the momentum generated by Juno OTC's initial collaboration with Instapill for loperamide two-milligram RDT, equivalent to Imodium RDT, which is now widely distributed under private label across major Canadian retailers and delivering robust commercial performance.

Through this strategic partnership with Instapill, a global leader in rapid-dissolve technology, LSL Pharma, through its private label division Juno OTC Inc., secures access to a pipeline of innovative dosage formats designed for convenience, speed and enhanced patient compliance. The company is actively advancing additional OTC RDT products with the goal of building a broad, high-volume portfolio across multiple therapeutic categories.

"Signing this term sheet with Instapill is a testament to Juno OTC's execution capabilities and accelerates our growth trajectory in the consumer health space," said Francois Roberge, president and chief executive officer of LSL Pharma. "The strong market adoption of our loperamide RDT has validated our commercialization model and confirms the potential of our RDT platform. By expanding into high-demand categories like loratadine, we are positioning Juno OTC as a leading supplier of innovative, high-quality private label RDT products in Canada. With proven commercial traction and a growing pipeline, we are well positioned to drive sustainable revenue growth and deliver long-term shareholder value."

With more than 40 products currently on the market and 10 new products expected to be launched over the next 12 months, Juno OTC is rapidly increasing its presence in the pharmaceutical OTC market in Canada.

About Juno OTC Inc.

Juno OTC is a leading supplier in the Canadian private label consumer health care OTC market providing key Canadian retailers with core product offerings under the retailers' own recognized private label brands and strategic new opportunities to build the mutual business. With a strong legacy in this market, Juno OTC is recognized for providing the highest-quality products along with a record of partnership with these Canadian retailers to build their overall presence and success in consumer health care. Juno OTC has all required Health Canada licences for importing and distributing these products, along with tremendous expertise in all areas of regulatory and quality assurance that is required for the Canadian market.

About LSL Pharma Group Inc.

LSL Pharma Group is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Leveraging its technical expertise, certified facilities and experienced team, LSL Pharma delivers high-quality solutions that meet the highest industry standards. The wholly owned subsidiaries of LSL Pharma include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Sante Inc., Dermolab Pharma Ltd., Laboratoire Du-Var Inc. and Juno OTC.

We seek Safe Harbor.